Measures to Nosocomial Infections Prevention by Carbapenems-resistant Bacteria in an Andalusian Hospital

Measures to Nosocomial Infections Prevention by Carbapenems-resistant Bacteria in an Andalusian Hospital

Main Article Content

Francisco Javier Antúnez Rodríguez
Ana García Duque
Adrián Jiménez Salido

Abstract

The appearance and expansion of carbapenem producing bacteria constitute a global threat of infections without effective treatment. These bacteria usually offer resistance to all antimicrobial of the first-line, producing infections that are very difficult to treat. carbapenem are antimicrobial of wide spectre and high potenty, and due to that they’re used in patients with serious infections, even when a prior risk to have infection by multi-resistant bacteria (MDR) is low. A great tendency exists to keep the same antibiotic from the beginning of treatment until its end, despite the lack of risk factors to have an infection by bacteria MDR. All this produces an avoidable increase of carbapenem antibiotic consumption. Our objective is to analyze if the infection incidence/colonization by Pseudomona aeruginosa in an Andalusian hospital is reduced after the implantation of a set of persuasive measures directed to the optimization of the treatments with carbapenem and to analyze the consumption of carbapenem antibiotics. The method used in an quasiexperimental-ecological study of temporal series from an Andalusian hospital and a quarterly evaluation of indicators.

References

Cisneros, J.M., Neth, O., Gil-Navarro, M.V., Lepe, J.A., Jiménez-Parrilla, F., Cordero, E.,
Rodríguez-Hernández, M.J., Amaya-Villar, R., Cano, J., Gutiérrez-Pizarraya, A., GarcíaCabrera,
E., y Molina, J. (2014). Global impact of an educational antimicrobial
stewardship programme on prescribing practice in a tertiary hospital centre. Clinical
Microbiology and Infection, 20(1), 82-88.

Control, E.C. (2011). Risk assessment on the spread of carbapenemase-producing
Enterobacteriaceae (CPE) through patients transfer between healthcare facilities, with
especial emphasis on crossborder transfer. Stockholm: ECDC.

Evans, B.A., Hamouda, A., y Amyes, S.G. (2013). The rise of carbapenem-resistance:
Acinetobacter baumannii. Phrmaceutical Design, 19, 223-238.

Gauzit, R., Pean, Y., Alfandari, S., Bru, J.P., Bedos, J.P., (2015.). Carbapenem use in French
hospitals: A nationwide survey at the patient level. International Journal
Antimicrobiology Agents, 46(6), 707-712.

Liu, Q., Li, W., Feng, Y., y Tao, C. (2014). Efficacy and Safety of Polymyxins for the Treatment
of Acinectobacter baumannii Infection: A Systematic Review and Meta-Analysis. PLos
One, 9(6), e98091.

Marya, D.Z.M. (2016). Secular trends in Acinetobacter baumannii resistance in resiratory and
blood stream specimens in the United States, 2003 to 2012: A survey study. Journal
Hospital Medical, 11(1), 21-26.

Nakamura, A. et al. (2013). Meropenem as predictive risk factor for isolation of multidrugresistant
Pseudomonas aeruginosa. Journal Hospiotal Infection, 83(2), 153-155.

PIRASOA (2016). Informe cuarto trimestre e Iras anual. Sevilla: Servicio Andaluz de Salud.

PIRASOA (s.f.). Programa integral de prevención y control de las infecciones relacionadas con
la asistencia sanitaria y uso apropiado de los antimicrobianos.

PIRASOA, A.M. (s.f.). Indicadores de proceso y estructura programas PROA.

PIRASOA, I. (s.f.). Programa integral de prevención, control de las infecciones relacionadas con
la asistencia sanitaria, y uso apropiado de los antimicrobianos.

Qin, W. et al. (2014). Hospital clonal dissemination of Enterobacter aerogenes producing
carbapenemase KPC-2 in a Chinese teaching hospital. Journal Medical Microbiology.
63(2), 222-228.

Servicio Andaluz de Salud, C. d. (2017). Informe segundo trimestre PIRASOA.

Servicio Andaluz de Salud, C. d. (2017). Informe tercer trimestre PIRASOA.

Servicio Andaluz de Salud, C. d. (s.f.). Informe primer trimestre PIRASOA.

Servico Andaluz de Salud, C. d. (2017). Informe primer, segundo y tercer trimestre del Programa
PIRASOA.

Tängdén, T. et al. (2015). Global dissemination of extensively drug-resisitant carbapenemaseproducing
Enterobacteriaceae: clinical perspectives on detección, tretment and infection
control. Journal International Medical, 277(5), 501-512.

World Health Organization (2014). Antimicrobial resistance: global reporto on surveillance.
Geneva: WHO.